Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 2Hodgkin Disease 2Waldenstrom Macroglobulinemia 1Stomach Neoplasms 1Rectal Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Decitabine 4Cyclophosphamide 4ruxolitinib 3fludarabine phosphate 3Filgrastim 3Etoposide 3Topotecan 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Methylprednisolone 2LY2784544 2Cytarabine 2Carboplatin 2Antilymphocyte Serum 2veliparib 1umbralisib 1tipifarnib 1talazoparib 1spartalizumab 1sonidegib 1sargramostim 1sabatolimab 1romidepsin 1pyroxamide 1peginterferon alfa-2a 1nelarabine 1navitoclax 1fresolimumab 1durvalumab 1arsenous acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Polycythemia Vera × umbralisib × Clear all
NCT02493530 2026-05-19

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Vanderbilt-Ingram Cancer Center

Phase 1 Completed
60 enrolled
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡